NEW YORK--(BUSINESS WIRE)--IntelliCell BioSciences Inc. (“IntelliCell” or the “Company”) today announced that its previously announced merger with Media Exchange Group, Inc. (“MEG”) (OTCQB: CWLCD) has been completed. As a result of the merger, IntelliCell is now a wholly-owned subsidiary of MEG. IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adipose (fat) derived stromal vascular fraction. Following the completion of the merger, MEG will be renamed IntelliCell Biosciences, Inc. to better reflect its new business direction and the principal business operations of the company going forward will be IntelliCell’s business. Additionally, the company anticipates adopting a new ticker symbol on the OTCQB in the near future.
